Department of Endocrinology, Tianjin First Center Hospital, 24 Fukang Road, Nankai District, Tianjin, 300192, China.
Department of Cardiovascular Medicine, Tianjin First Center Hospital, Tianjin, 300192, China.
Lipids Health Dis. 2017 Dec 2;16(1):227. doi: 10.1186/s12944-017-0609-0.
This study is to compare the effects of Liraglutide and Metformin alone or combined treatment on the cardiac function in T2DM patients complicated with CAD.
120 T2DM patients were included at Endocrinology Department of Tianjin First Center Hospital (Tianjin, China) from April 2012 to September 2013. The study contained two sections. Section 1: 30 patients in group 1 was treated with Liraglutide (Novo Nordisk) (1.2 mg/d), and 30 patients in group 2 with Metformin (Shiguibao) (1500 mg/d) for 24 weeks. Section 2: 30 patients in group1 was treated with Liraglutide (1.8 mg/d) and 30 in group 2 with Liraglutide (1.2 mg/d) plus Metformin (1500 mg/d) for 24 weeks. Fasting blood glucose (FBG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), body mass index (BMI), blood pressure (BP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), C reactive protein (CRP), left ventricular end-diastolic diameter (LVEDD), ejection fraction (EF) and the ratio of early (E) to late (A) ventricular filling velocities (E/A ratio) were measured before and after the 24-week treatment.
After 24-week treatment, when blood glucose level was controlled in 4 groups, Liraglutide alone treatment showed better improvements than on all measuring except TG in Section 1, however, combined treatment of Liraglutide and Metformin showed better improvements on all measuring except BMI, TG and BP in Section 2.
With similar glycemic control, the Liraglutide (1.2 mg/d) monotherapy showed the better effects than either Metformin alone, or combination of Liraglutide and Metformin on lipid metabolism and cardiovascular function.
This trial was registered at Chinese Clinical Trial Registry ( chictr.org.cn ) # ChiCTR-IPR-16008578 .
本研究旨在比较利拉鲁肽和二甲双胍单独或联合治疗对合并 CAD 的 T2DM 患者心功能的影响。
2012 年 4 月至 2013 年 9 月，天津第一中心医院内分泌科共纳入 120 例 T2DM 患者。该研究包含两个部分。第 1 部分：1 组 30 例患者给予利拉鲁肽（诺和诺德）（1.2mg/d）治疗，2 组 30 例患者给予二甲双胍（石龟宝）（1500mg/d）治疗 24 周。第 2 部分：1 组 30 例患者给予利拉鲁肽（1.8mg/d）治疗，2 组 30 例患者给予利拉鲁肽（1.2mg/d）联合二甲双胍（1500mg/d）治疗 24 周。测量治疗前及治疗 24 周后空腹血糖（FBG）、餐后血糖（PPG）、糖化血红蛋白（HbA1c）、体重指数（BMI）、血压（BP）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、C 反应蛋白（CRP）、左室舒张末期直径（LVEDD）、射血分数（EF）和早期（E）与晚期（A）心室充盈速度比（E/A 比）。
4 组血糖控制达标后，1 组利拉鲁肽单药治疗除 TG 外，其余各指标改善均优于其他各组，但 2 组利拉鲁肽联合二甲双胍治疗除 BMI、TG 和 BP 外，其余各指标改善均优于其他各组。
在血糖控制相似的情况下，利拉鲁肽（1.2mg/d）单药治疗在改善血脂代谢和心血管功能方面优于二甲双胍单药治疗或利拉鲁肽联合二甲双胍治疗。
本试验在中国临床试验注册中心（ chictr.org.cn ）注册，注册号为 ChiCTR-IPR-16008578。
